Across TCGA pan-cancer cohorts, FADS3 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of FADS3’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where FADS3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types FADS3 is over-expressed in tumor, although a few such as LUAD and HNSC show the opposite, repressed pattern.

CCRCC, LUAD, and HNSC are the cancer types where FADS3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FADS3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	II,III,IV	+0.547	<.001	8	view →
LUAD	Male	II,III,IV	−0.361	<.001	7	view →
HNSC	All	II,III,IV	−0.443	.018	4	view →
LSCC	Male	All	−0.209	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: FADS3 RNA expression & survival · all FADS3 data types